Table 6.
Risk factors for the development of SMN in cHL and DLBCL survivors
| cHL patients | DLBCL patients | |||||
|---|---|---|---|---|---|---|
| N | RR (95% CI) | P-value | N | RR (95% CI) | P-value | |
| Age at transplant, years | <.001 | <.001 | ||||
| 15–39 | 570 | 1.00 | 182 | 1.00 | ||
| 40–54 | 145 | 1.54 (0.73–3.25) | 0.25 | 252 | 3.42 (1.14–10.23) | 0.03 |
| 55+ | 52 | 5.20 (2.38–11.36) | <.01 | 271 | 13.56 (4.76–38.63) | <.01 |
| Number of lines of chemotherapy | 0.015 | Not significant | ||||
| 1 | 88 | 1.00 | ||||
| 2 | 428 | 0.95 (0.32–2.84) | 0.92 | |||
| 3 | 177 | 2.31 (0.77–6.94) | 0.14 | |||
| 4+ | 57 | 2.57 (0.72–9.15) | 0.14 | |||
| Missing | 17 | 6.36 (1.12–36.01) | 0.04 | |||